Recent studies reveal an intriguing side effect of SGLT2 inhibitors and GLP-1 agonists: they significantly reduce the risk of Alzheimer’s disease among diabetics. According to data from the National Institutes of Health (NIH), SGLT2 inhibitors lower the risk by an impressive 43%, while GLP-1 agonists reduce it by 33%. Long-term studies from the UK back up these findings, indicating that under GLP-1 therapy, only 2.3 dementia cases were documented per 1,000 person-years compared to 3.1 in the control group. For context, DPP-4 inhibitors reported 4.4 cases.
Mixed Results from Clinical Trials
However, not all studies present a positive outlook. The Phase 3 trials, evoke and evoke+ by Novo Nordisk, depict a more nuanced picture. Over 3,800 participants exhibiting early signs of Alzheimer’s were administered Semaglutide or a placebo. Results showed no significant clinical advantage in disease progression. Although specific biomarkers improved, cognitive decline did not slow down, leading Novo Nordisk to cancel the planned expansion study.
Similarly, Tirzepatide fell short in observational studies. While it demonstrated a reduced incidence of mild cognitive impairment, it failed to show robust effects on actual Alzheimer’s disease.
New Antibody Therapies Available in Germany
The market for GLP-1 therapies is booming, with industry forecasts predicting a volume exceeding $100 billion by 2030. Recently, a Medicare program in the USA has kicked off, offering GLP-1 medications for obesity to approximately three million seniors for a monthly copayment of $50.
In Germany, two new antibody therapies, Lecanemab and Donanemab, have become available. These target amyloid plaques in the brain, and it is estimated that around 120,000 of Germany’s 1.2 million Alzheimer’s patients are eligible for treatment. The annual costs associated with dementia in Germany surpass €80 billion, and alarmingly, about 60% of affected individuals remain undiagnosed.
Given that many individuals go without a professional diagnosis for extended periods, early detection of warning signs is crucial for management. A free 7-question self-assessment can provide a discreet evaluation of potential dementia signs in just two minutes. Take the free dementia self-test anonymously now
AI Detects Alzheimer’s Years Ahead of Symptoms
Exciting advancements in digital diagnostics are emerging. AI-driven retinal scans, according to data from the UK Biobank, can identify the risk of Alzheimer’s an astounding 8.5 years before symptoms occur. This technology market is expected to grow from $2.65 billion in 2023 to approximately $9.4 billion by 2033.
New blood tests focusing on the biomarker pTau217 are achieving over 90% accuracy in detecting amyloid pathologies. Experts emphasize the importance of early detection, especially as other factors elevate risk. Anticholinergics increase dementia risk by 54%, and proton pump inhibitors by 44%. Chronic low blood pressure reportedly increases risk by a factor of 2.74, according to US studies.
Lifestyle as a Protective Factor
Beyond medications, everyday factors significantly influence dementia risk. For instance, using hearing aids reduces the risk by 23%, while adherence to a Mediterranean diet may lower it by up to 30%. Interestingly, regular use of computers or smartphones is associated with a 25% slowdown in cognitive decline.
As new therapies and digital diagnostics revolutionize medicine, maintaining active mental fitness in daily life remains one of the essential pillars of prevention. A guide provides practical exercises and valuable dietary tips to keep your brain functioning well into old age. Secure the free brain training guide now
Additionally, researchers at the University of Utah are exploring the Arc protein, which facilitates the spread of toxic tau protein between brain cells. These insights could serve as a foundation for new therapies aimed at blocking the spread of pathological proteins. Even dental preventive measures play a significant role; estimates suggest that 2-4% of dementia cases could be avoided through proper oral care.
